ArticleCancers2024

Biomarker Analysis from a Phase I/Ib Study of Regorafenib and Nivolumab in Mismatch Repair-Proficient Advanced Refractory Colorectal Cancer.

Dae Won Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.